A man works on calculations at a desk with medicine blisters and a computer displaying data.
The ongoing conflict involving Iran is expected to exert upward pressure on the prices of essential drugs in India. According to industry sources, consumers may experience a 3-5% increase in prices, effectively negating the benefits gained from the Goods and Services Tax (GST) rate cuts implemented in late September.
The pharmaceutical industry anticipates that the price surge will remain in effect for approximately 3-4 months. However, there is a potential rollback option if input costs stabilize during this period.
The price hike reflects the broader impact of geopolitical tensions on the pharmaceutical supply chain. The industry will continue to monitor the situation and adjust pricing strategies as needed.
About the Author
